跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PEG IL-2
首页
药物
PEG IL-2
PEG IL-2
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHOD OF PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES
EP 3896079 A4
申请人: JENKEM TECH CO LTD TIANJIN
优先权: 2018
CN
EP
US
WO
4 件公开
MODIFIED IL-2 PROTEINS, PEG CONJUGATES, AND USES THEREOF
US 2022324932 A1
申请人: CSPC MEGALITH BIOPHARMACEUTICAL CO LTD
优先权: 2019
CN
US
WO
4 件公开
METHOD FOR REALIZING CONTROLLED RELEASE AND SUSTAINED RELEASE OF ACTIVITY OF BIOACTIVE MOLECULES AND USE FOR DRUGS
US 20250154217 A1
申请人: ZONHON BIOPHARMA INST INC
优先权: 2022
CN
US
WO
3 件公开
SITE-SPECIFIC COUPLED PEGYLATED INTERLEUKIN-2 MUTANT WITH RECEPTOR AFFINITY PREFERENCE AND USE THEREOF
EP 4631972 A1
申请人: NANJING NOVOACINE BIOTECHNOLOGY CO LTD
优先权: 2022
CN
EP
WO
3 件公开
CANCER THERAPY WITH IL-2 PEG CONJUGATES
EP 4683671 A1
申请人: SYNTHORX INC
优先权: 2023
CN
EP
WO
3 件公开
Modified IL-2 variants that selectively activate regulatory T cells
US 10035836 B1
申请人: DELINIA INC
优先权: 2014
CN
US
3 件公开
PEGylated soluble gp130-dimers useful as a medicament
EP 1491554 A1
申请人: CONARIS RES INST AG
优先权: 2003
EP
Method for producing human interleukin 6 by high-density fermentation
CN 101736009 B
申请人: GUANGZHOU INST BIOMED & HEALTH
优先权: 2009
CN
Method for preparing PEGylated biomolecules with controllable binding sites
CN 113121671 A
申请人: TIANJIN JENKEM TECH CO LTD
优先权: 2020
CN
二取代PEG化白细胞介素2及其制备方法、应用
CN 113121670 B
申请人: 天津键凯科技有限公司
优先权: 2020
CN
第 1 / 3 页
上一页
下一页
药物
反馈